ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Agents targeting lymphoid or myeloid cells surface antigens [II]: CD22, CD30, CD33,

Specific management strategies should be put in place to reduce the risk and/or the severity of infectious complications associated to the reviewed agents.